sakai hitomi 酒井瞳

… Alternative Names

酒井瞳サカイヒトミ

Less

Researcher Number	20714736
Other IDs
Affiliation (Current)	2026: 昭和医科大学, 大学共同利用機関等の部局等, 准教授
Affiliation (based on the past Project Information) *help	2024: 昭和大学, 大学共同利用機関等の部局等, 准教授 2022 – 2023: 昭和大学, 大学共同利用機関等の部局等, 講師
Review Section/Research Field	Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related
Keywords	Principal Investigator 癌性髄膜炎 / リキッドバイオプシー / circulating tumor DNA / 髄膜播種 / 脳転移 / 乳癌

Assessment of cerebrospinal fluid ctDNA for the development of systemic therapy for brain metastases and leptomeningea disease of HER2-negative breast cancerPrincipal Investigator
- Principal Investigator
  
  酒井瞳
- Project Period (FY)
  2022 – 2025
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Showa University

All 2025 2024 2023 2022

All Journal Article Presentation

[Journal Article] Management of nausea and vomiting induced by antibody drug conjugates2025
- Author(s)
  Farhat Jawhara、Sakai Hitomi、Tsurutani Junji
- Journal Title
  
  Breast Cancer
  
  Volume: 32 Issue: 2 Pages: 278-285
- DOI
  10.1007/s12282-025-01670-1
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K07216, KAKENHI-PROJECT-22K15565
[Journal Article] A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)2025
- Author(s)
  Sakai H.、Tsurutani J.、Ozaki Y.、Ishiguro H.、Nozawa K.、Yamanaka T.、Aogi K.、Matsumoto K.、Iwasa T.、Tokiwa M.、Tsuneizumi M.、Miyoshi Y.、Kitagawa C.、Yamamoto M.、Takano Y.、Imamura C.K.、Chiba Y.、Takiguchi D.、Ezumi T.、Takano T.
- Journal Title
  
  Annals of Oncology
  
  Volume: 36 Issue: 1 Pages: 31-42
- DOI
  10.1016/j.annonc.2024.09.001
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K07216, KAKENHI-PROJECT-22K15565
[Journal Article] Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)2023
- Author(s)
  Masuda J, Sakai H, Tsurutani J, et al.
- Journal Title
  
  J Immunother Cancer.
  
  Volume: 11 Issue: 9 Pages: e007126-e007126
- DOI
  10.1136/jitc-2023-007126
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K15565, KAKENHI-PROJECT-22K07216, KAKENHI-PROJECT-21K08785
[Journal Article] Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)2023
- Author(s)
  Masuda H, Tanabe Y, Sakai H, et al.
- Journal Title
  
  Breast.
  
  Volume: 71 Pages: 22-28
- DOI
  10.1016/j.breast.2023.07.003
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)2023
- Author(s)
  Sakai H, Tsurutani J, Ozaki Y, et al.
- Journal Title
  
  BMJ Open .
  
  Volume: 3 Issue: 4 Pages: e070304-e070304
- DOI
  10.1136/bmjopen-2022-070304
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] Comparison of older and younger patients with ovarian cancer: A post hoc study ( <scp>JGOG3016‐A3</scp> ) of the treatment strength and prognostic outcomes of conventional or dose‐dense chemotherapy2023
- Author(s)
  Itani Yoshio、Sakai Hitomi、Hamano Tetsutaro、Asai‐Sato Mikiko、Futagami Masayuki、Fujimura Masaki、Aoki Yoichi、Suzuki Nao、Yoshida Yoshio、Enomoto Takayuki
- Journal Title
  
  Journal of Obstetrics and Gynaecology Research
  
  Volume: - Issue: 5 Pages: 1400-1411
- DOI
  10.1111/jog.15620
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] 乳がん診療の進歩と展望乳がんにおける抗体薬物複合体(ADC)の展望2022
- Author(s)
  酒井瞳
- Journal Title
  
  月刊腫瘍内科 (腫瘍内科)
  
  Volume: 30
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] HBOC診療の現状と今後の展開 HBOCにおける新規薬物療法:PARP阻害薬2022
- Author(s)
  酒井瞳
- Journal Title
  
  乳癌の臨床 (Japanese Journal of Breast Cancer)
  
  Volume: 37
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] 周術期薬物療法up to date HER2陽性乳癌の周術期薬物療法2022
- Author(s)
  酒井瞳
- Journal Title
  
  乳癌の臨床 (Japanese Journal of Breast Cancer)
  
  Volume: 38
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] 女性のがん~治療とケアの最前線~治療の最前線転移再発乳がんの最新治療~薬物療法~2022
- Author(s)
  酒井瞳
- Journal Title
  
  がん看護 (Japanese Journal of Cancer Care)
  
  Volume: 27
- Data Source
  KAKENHI-PROJECT-22K15565
[Journal Article] Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey2022
- Author(s)
  Asai-Sato Mikiko、Suzuki Nao、Sakai Hitomi、Itani Yoshio、Sato Shinya、Futagami Masayuki、Yoshida Yoshio
- Journal Title
  
  Journal of Gynecologic Oncology
  
  Volume: 34 Issue: 1
- DOI
  10.3802/jgo.2023.34.e10
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K15565, KAKENHI-PROJECT-23K24483
[Presentation] 1816O - A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B2024
- Author(s)
  Hitomi Sakai, Junji Tsurutani, et al.
- Organizer
  ESMO congress 2024
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)2024
- Author(s)
  酒井瞳
- Organizer
  第21回日本臨床腫瘍学会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B2024
- Author(s)
  酒井瞳
- Organizer
  第21回日本臨床腫瘍学会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] SY09-2　生殖細胞系列BRCA1/2変異陽性乳癌の術後オラパリブ治療2023
- Author(s)
  酒井瞳
- Organizer
  第20回日本臨床腫瘍学会
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] Adjuvant Olaparib for patients with germline BRCA1/2 mutated breast cancer2023
- Author(s)
  酒井瞳
- Organizer
  第20回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] 西日本がん研究機構（WJOG)の若手ブレストオンコロジストを対象にした4か月間の臨床試験教育プログラムの報告2023
- Author(s)
  酒井瞳
- Organizer
  第20回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-22K15565
[Presentation] A randomized, double-blind, placebo-controlled study of olanzapine for CINV during T-DXd in HER2 positive metastatic breast cancer patients: WJOG14320B (ERICA)2022
- Author(s)
  Hitomi Sakai, Junji Tsurutani, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, Tsutomu Iwasa, Yasutaka Chiba, Yuji Hirakawa, and Toshimi Takano
- Organizer
  第30回日本乳癌学会
- Data Source
  KAKENHI-PROJECT-22K15565

1. 鶴谷純司

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results

sakai hitomi 酒井 瞳

酒井 瞳 サカイ ヒトミ

Research Projects

Research Products

Co-Researchers

Assessment of cerebrospinal fluid ctDNA for the development of systemic therapy for brain metastases and leptomeningea disease of HER2-negative breast cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Management of nausea and vomiting induced by antibody drug conjugates2025

Author(s)

Journal Title

DOI

Data Source

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Comparison of older and younger patients with ovarian cancer: A post hoc study ( <scp>JGOG3016‐A3</scp> ) of the treatment strength and prognostic outcomes of conventional or dose‐dense chemotherapy2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] 乳がん診療の進歩と展望 乳がんにおける抗体薬物複合体(ADC)の展望2022

Author(s)

Journal Title

Data Source

[Journal Article] HBOC診療の現状と今後の展開 HBOCにおける新規薬物療法:PARP阻害薬2022

Author(s)

Journal Title

Data Source

[Journal Article] 周術期薬物療法up to date HER2陽性乳癌の周術期薬物療法2022

Author(s)

Journal Title

Data Source

[Journal Article] 女性のがん~治療とケアの最前線~治療の最前線 転移再発乳がんの最新治療~薬物療法~2022

Author(s)

Journal Title

Data Source

[Journal Article] Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey2022

Author(s)

Journal Title

DOI

Data Source

Author(s)

Organizer

Data Source

[Presentation] Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)2024

Author(s)

Organizer

Data Source

[Presentation] Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B2024

Author(s)

Organizer

Data Source

[Presentation] SY09-2 生殖細胞系列BRCA1/2変異陽性乳癌の術後オラパリブ治療2023

Author(s)

Organizer

Data Source

[Presentation] Adjuvant Olaparib for patients with germline BRCA1/2 mutated breast cancer2023

Author(s)

Organizer

Data Source

sakai hitomi 酒井瞳

酒井瞳サカイヒトミ

[Journal Article] 乳がん診療の進歩と展望乳がんにおける抗体薬物複合体(ADC)の展望2022

[Journal Article] 女性のがん~治療とケアの最前線~治療の最前線転移再発乳がんの最新治療~薬物療法~2022

[Presentation] SY09-2　生殖細胞系列BRCA1/2変異陽性乳癌の術後オラパリブ治療2023